Genenta Science S.p.A.
GNTA · XNASCIK 1838716fmd_1ASZXHKPAPRMVP671MY20E8BDQManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Dec 31, 2025, 12 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Realized investment gains (losses) | – | – | – | – | – | 0 | – |
| Research and development | 4 | 5 | 3 | 5 | 6 | 5 | 3 |
| Total operating expenses | 5 | 6 | 6 | 11 | 12 | 10 | 7 |
| Operating income | (5) | (6) | (6) | (11) | (12) | (10) | (7) |
| Other non-operating income (expense) | 0 | (0) | 0 | 3 | 0 | 1 | 0 |
| Income before taxes | (5) | (6) | (6) | (8) | (12) | (9) | (7) |
| Net income | (5) | (6) | (6) | (8) | (12) | (9) | (7) |